Section Edited by Marcela V. Maus, MD, PhD
Immune cell therapies and cell engineering approaches, new targets, novel functionalities, clinical trial results, correlative studies in patients who have received cell-based therapies, novel engineering strategies (molecular switches, conditional expression, logic gating), gene-edited cells to knock out or knock in novel functions, synthetic gene circuits. Includes pre-clinical animal modeling (small and large) and clinical trials.
Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG miceShahryar Khoshtinat Nikkhoi, Ge Yang, Hajar Owji, Mayara Grizotte-Lake, Rick I Cohen, Lazaro Gil Gonzalez, Mohammad Massumi, Arash Hatefi
15 March 2024
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulationJiri Eitler, Wiebke Rackwitz, Natalie Wotschel, Venugopal Gudipati, Nivedha Murali Shankar, Anastasia Sidorenkova, Johannes B Huppa, Paola Ortiz-Montero, Corinna Opitz, Stephan R Künzel, Susanne Michen, Achim Temme, Liliana Rodrigues Loureiro, Anja Feldmann, Michael BachmannSee the full list of authors
27 February 2024
Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasisSarah L Ash, Rebecca Orha, Holly Mole, Meg Dinesh-Kumar, Steven P Lee, Frances K Turrell, Clare M Isacke
27 February 2024
Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapyStephanie N Shishido, Olivia Hart, Sujin Jeong, Aidan Moriarty, Darren Heeke, John Rossi, Adrian Bot, Peter Kuhn
12 February 2024
Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicityTamer Basel Shabaneh, Andrew R Stevens, Sylvia M Stull, Kristen R Shimp, Brandon W Seaton, Ekram A Gad, Carla A Jaeger-Ruckstuhl, Sylvain Simon, Amanda L Koehne, Jason P Price, James M Olson, Benjamin G Hoffstrom, David Jellyman, Stanley R Riddell
7 February 2024
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinomaRodabe Amaria, Anne Knisely, David Vining, Scott Kopetz, Michael J Overman, Milind Javle, Mara B Antonoff, Ching-Wei D Tzeng, Robert A Wolff, Shubham Pant, Kathryn Lito, Kelly Rangel, Bryan Fellman, Ying Yuan, Karen H LuSee the full list of authors
2 February 2024
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivityEmmanuelle Moraes Ribeiro, Kathy-Ann Secker, Ana-Maria Nitulescu, Rebekka Schairer, Hildegard Keppeler, Anton Wesle, Hannes Schmid, Anita Schmitt, Brigitte Neuber, Daniela Chmiest, Silvia Podavini, Melanie Märklin, Boris Klimovich, Michael Schmitt, Fulya KorkmazSee the full list of authors
31 January 2024
Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapyNatalie K. Horvat, Isaac Karpovsky, Maggie Phillips, Megan M. Wyatt, Margaret A. Hall, Cameron J. Herting, Jacklyn Hammons, Zaid Mahdi, Richard A. Moffitt, Chrystal M. Paulos, Gregory B. Lesinski
8 January 2024
Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantationChao Ma, Peng Chen, Jishan Du, Lu Wang, Ning Lu, Jiaojun Sun, Xu Qilong, Yu Wang, Liping Dou, Dai-Hong Liu
6 January 2024
Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemiaShifaa M. Abdin, Daniela Paasch, Arnold Kloos, Marco Carvalho Oliveira, Mi-Sun Jang, Mania Ackermann, Andriana Stamopoulou, Philipp J Mroch, Christine S Falk, Constantin S von Kaisenberg, Axel Schambach, Michael Heuser, Thomas Moritz, Gesine Hansen, Michael MorganSee the full list of authors
22 December 2023